

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE PCT NATIONAL STAGE APPLICATION OF  
AUSBORN ET AL.  
INTERNATIONAL APPLICATION NO: PCT/EP03/13776  
FILED: 5 DECEMBER 2003  
U.S. APPLICATION NO: 10/537,038  
35 USC §371 DATE: 21 NOVEMBER 2005  
FOR: MICROPARTICLES PREPARED USING AN IONIC LIQUID

**MS: Amendment**  
Commissioner for Patents  
PO Box 1450  
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT


Sir:

This paper is supplemental to the Information Disclosure Statement filed June 1, 2005. Since Applicants believe this paper is being filed before the mailing date of a first Office Action on the merits, no fees are believed to be required under 37 C.F.R. §1.97(b)(3). If a fee is deemed to be required, the Commissioner is hereby authorized to charge such fee to Deposit Account No. 19-0134.

In accordance with 37 C.F.R. §1.56, applicants wish to call the Examiner's attention to the references cited on the attached form(s) PTO-1449.

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

Respectfully submitted,

  
John W. Kung  
Attorney for Applicants  
Reg. No. 44,199

Novartis Pharmaceuticals Corp.  
Patents Pharma  
One Health Plaza, Building 104  
East Hanover, NJ 07936-1080  
(862) 778-7877

Date:

*Aug. 4, 2000*